Gruber, L.; Abdelfatah, S.; Fröhlich, T.; Reiter, C.; Klein, V.; Tsogoeva, S.B.; Efferth, T.
Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds. Molecules 2018, 23, 841.
https://doi.org/10.3390/molecules23040841
AMA Style
Gruber L, Abdelfatah S, Fröhlich T, Reiter C, Klein V, Tsogoeva SB, Efferth T.
Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds. Molecules. 2018; 23(4):841.
https://doi.org/10.3390/molecules23040841
Chicago/Turabian Style
Gruber, Lisa, Sara Abdelfatah, Tony Fröhlich, Christoph Reiter, Volker Klein, Svetlana B. Tsogoeva, and Thomas Efferth.
2018. "Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds" Molecules 23, no. 4: 841.
https://doi.org/10.3390/molecules23040841
APA Style
Gruber, L., Abdelfatah, S., Fröhlich, T., Reiter, C., Klein, V., Tsogoeva, S. B., & Efferth, T.
(2018). Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds. Molecules, 23(4), 841.
https://doi.org/10.3390/molecules23040841